Metabolic plasticity of activated immune cells: advantages for suppression of covid-19 disease by melatonin

COVID-19 has infected hundreds of thousands and killed tens of thousands of people worldwide and it continues to ravage societies as well as the fiscal and economic stability of several countries. Currently, several drugs that were designed for other conditions have been repurposed to counter the COVID-19 pandemic. Some have modest efficacy in resisting this disease, but all of them have significant toxicity. Several pharmaceutical companies are rushing to develop vaccines, but their availability is 12 to 18 months in the future. In the meantime, readily available, and affordable molecules that will have utility as COVID-19 antidotes are being sought. Almost simultaneously, several groups independently recently proposed that melatonin should be considered for this purpose, and several trials are underway to test whether melatonin is a reliable candidate drug for COVID-19 treatment. In this brief review, we described some potential mechanisms by which melatonin will work to protect against a COVID-19 infection. Of particular note is the likely ability of melatonin to force activated immune cells to abandon aerobic glycolysis in favor of mitochondrial oxidative phosphorylation. Aerobic glycolysis gives proinflammatory activated immune cells, for example, macrophages, an opportunity to produce increased amounts of cytokines which are released as the cytokine storm and the associated significant increase in oxidative stress is accepted as a major contributing factor to the bronchoalveolar dysfunction and pneumonia that occurs in COVID-19 infected individuals. Melatonin, via similar processes, may reduce the formation of proinflammatory MI macrophages and convert them to macrophages of the MII phenotype, which are anti-inflammatory. These are not the only mechanisms by which melatonin may protect against the deadly COVID-19 pandemic. Melatonin could also be given as an adjuvant with other toxic pharmaceutical agents with a high likelihood it would reduce their side effects.Fil: Reiter, Russel. UT Health Science Center at San Antonio; Estados UnidosFil: Sharma, Ramaswamy. UT Health Science Center at San Antonio; Estados UnidosFil: Ma, Qiang. UT Health Science Center at San Antonio; Estados UnidosFil: Liu, Changwei. Peking Union Medical College Hospital; ChinaFil: Manucha, Walter Ariel Fernando. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Mendoza. Instituto de Medicina y Biología Experimental de Cuyo; Argentina. Universidad del Aconcagua. Facultad de Ciencias Médicas; ArgentinaFil: Abreu Gonzalez, Pedro. Universidad de La Laguna; EspañaFil: Dominguez Rodriguez, Alberto. Universidad de La Laguna; Españ